Dr. Abou-Alfa on Trials Investigating Immunotherapy in HCC

Ghassan K. Abou-Alfa, MD
Published: Wednesday, Jun 21, 2017



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

The field of immunotherapy is moving very rapidly based on solid data, explains Abou-Alfa. Preclinical data demonstrate that evidence is there regarding PD-1/PD-L1 expression as well as other markers for checkpoint inhibitors.

The CheckMate-040 trial, which is investigating nivolumab (Opdivo) in patients with HCC, demonstrated that nearly 260 patients had a continued response rate of 20%.
 


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

The field of immunotherapy is moving very rapidly based on solid data, explains Abou-Alfa. Preclinical data demonstrate that evidence is there regarding PD-1/PD-L1 expression as well as other markers for checkpoint inhibitors.

The CheckMate-040 trial, which is investigating nivolumab (Opdivo) in patients with HCC, demonstrated that nearly 260 patients had a continued response rate of 20%.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x